ALCON RESEARCH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Next Generation Ophthalmic Irrigating Solution Posterior Segment Study

Phase 3

Completed

Conditions: Eye Diseases

Interventions: Drug: Next Generation Ophthalmic Irrigating Solution (NGOIS)
Other: BSS Plus

First Posted Date: 2006-06-02

Last Posted Date: 2012-03-05

Lead Sponsor: Alcon Research

Target Recruit Count: 369

Registration Number: NCT00333203

Locations: 🇺🇸
United States, Fort Worth, Texas, United States

Anecortave Acetate Risk Reduction Trial (AART)

Phase 3

Terminated

Conditions: AMD

Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
Other: Anecortave Acetate Vehicle
Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL

First Posted Date: 2006-06-02

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 36

Registration Number: NCT00332657

Locations: 🇮🇳
India, Bangalore, India

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Glaucoma

Interventions: Drug: Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)
Drug: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)
Other: Timolol Vehicle

First Posted Date: 2006-06-02

Last Posted Date: 2016-11-18

Lead Sponsor: Alcon Research

Target Recruit Count: 319

Registration Number: NCT00333125

AL-15469A for the Treatment of Bacterial Conjunctivitis

Phase 3

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%
Drug: Moxifloxacin hydrochloride ophthalmic solution 0.5% as base

First Posted Date: 2006-06-01

Last Posted Date: 2016-11-18

Lead Sponsor: Alcon Research

Target Recruit Count: 695

Registration Number: NCT00332293

Locations: 🇺🇸
Contact Alcon for Trial Locations, Fort Worth, Texas, United States

AL-15469A for the Treatment of Bacterial Conjunctivitis

Phase 3

Completed

Conditions: Bacterial Conjunctivitis

First Posted Date: 2006-05-31

Last Posted Date: 2009-09-29

Lead Sponsor: Alcon Research

Target Recruit Count: 600

Registration Number: NCT00331916

Locations: 🇺🇸
US, Fort Worth, Texas, United States

Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

Phase 3

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Olopatadine Hydrochloride Ophthalmic Solution Vehicle
Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

First Posted Date: 2006-05-31

Last Posted Date: 2017-08-14

Lead Sponsor: Alcon Research

Target Recruit Count: 287

Registration Number: NCT00331500

A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief

Phase 4

Completed

Conditions: Photorefractive Keratectomy

Interventions: Drug: nepafenac 0.1%
Other: ketorolac 0.4%

First Posted Date: 2006-05-29

Last Posted Date: 2016-11-18

Lead Sponsor: Alcon Research

Target Recruit Count: 40

Registration Number: NCT00330798

Locations: 🇺🇸
Lackland Air Force Base, San Antonio, Texas, United States

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

First Posted Date: 2006-05-16

Last Posted Date: 2016-11-18

Lead Sponsor: Alcon Research

Target Recruit Count: 88

Registration Number: NCT00326092

Locations: 🇺🇸
Fort Worth and Other Sites, Fort Worth, Texas, United States

Anecortave Acetate in Patients With Open-angle Glaucoma

Phase 2

Completed

Conditions: Open-angle Glaucoma

Interventions: Drug: Anecortave Acetate Sterile Suspension, 6 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL
Other: Anecortave Acetate Vehicle

First Posted Date: 2006-05-03

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 86

Registration Number: NCT00320203

Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

Phase 2

Completed

Conditions: Eye Diseases

Interventions: Drug: Anecortave Acetate Sterile Suspension, 6 mg/mL
Drug: Anecortave Acetate Suspension Depot, 30 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL
Other: Anecortave Acetate Vehicle

First Posted Date: 2006-04-19

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 70

Registration Number: NCT00315640

Locations: 🇵🇷
Bayamon, Bayamon, Puerto Rico
🇭🇺
Budapest, Budapest, Hungary
🇳🇱
Amsterdam, Amsterdam, Netherlands

and more 8 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy